ProBio Amplifies New Jersey’s Biotech Scene with 128K SF Expansion

ProBio Inc, a contract development and manufacturing organization (CDMO) based in New Jersey, has announced the opening of a state-of-the-art facility in Hopewell, New Jersey. This new site will serve as the central hub for their North American operations, significantly enhancing their ability to support cell and gene therapy manufacturing across the continent.

Facility Features and Capabilities

The Hopewell facility spans approximately 128,000 square feet and includes office, laboratory, and manufacturing spaces. It is equipped with the latest technology for process development and current good manufacturing practice (cGMP) production of plasmid DNA and viral vectors, including adeno-associated virus, lentivirus, and retrovirus. This site will handle tech transfer, method and analytical development, process development, and the manufacturing of both clinical and commercial-grade plasmid DNA and viral vector-based therapies. All operations will adhere to strict quality control and assurance processes.

Industry Recognition and Commitment to Excellence

Earlier this year, ProBio received the 2024 CDMO Leadership Award in Compatibility, Quality, and Reliability from Industry Standard Research and Life Science Connect. This award highlights ProBio’s excellence in manufacturing and delivering transformative therapies to the biotech and pharmaceutical sectors.

Leadership Perspectives

Li Chen, CEO of ProBio Inc, emphasized the company's commitment to expanding its capabilities to support the growing cell and gene therapy industry. The new facility in Hopewell, combined with a talented team, aims to expedite the delivery of life-changing therapies to patients. Patrick Liu, Chairman of ProBio Inc, highlighted that the Hopewell facility exemplifies their mission to bring innovative therapies from concept to reality, enhancing the rapid development and efficient delivery of novel treatments.

Future Plans and Enhancements

The facility’s cGMP suites will undergo renovations to produce plasmid DNA and viral vectors for various program phases. This expansion will strengthen ProBio’s leading position in the biotech sector and enhance their manufacturing capabilities.

About ProBio Inc

ProBio Inc is a fully integrated end-to-end CDMO based in New Jersey. The company focuses on enabling biotech and pharmaceutical companies to accelerate novel drug development and supply for clinical trials through to commercialization. With a strong commitment to quality and innovation, ProBio partners with biotech companies worldwide to expedite the delivery of advanced therapies to patients in need.